Semaglutide in the treatment of obesity and overweight
DOI:
https://doi.org/10.33448/rsd-v12i3.40656Keywords:
GLP-1 agonists; Semaglutide; Obesity; Medicine.Abstract
Introduction: The increasing prevalence of obesity in recent decades has become a major health problem worldwide. Semaglutide 2.4 mg once weekly was approved by the FDA in June 2021 for the treatment of overweight/obese individuals. The purpose of this study is to investigate the efficacy and safety of semaglutide in the treatment of obesity in patients who do not have diabetes mellitus. Methodology: This is an integrative literature review that qualitatively addresses the efficacy of semaglutide in the treatment of obesity and overweight. The guiding question was: "Is semaglutide effective in the treatment of obesity and overweight? The search occurred in the main databases, using the descriptors "semaglutide", "obesity", and "overweight". After applying all inclusion and exclusion criteria, a sample of 6 studies was obtained. Results and discussion: The articles exposed in this study served to consolidate the safety and efficacy of the use of subcutaneous semaglutide at a dose of 2.4 mg in non-diabetic patients in order to promote weight loss and reduce cardiometabolic risk. This medication has been shown to be superior to placebo and to another GLP-1 agonist, liraglutide. The main adverse effects are gastrointestinal reactions such as nausea and diarrhea, which tend to decrease over time, as observed in clinical trials. Conclusion: The use of semaglutide has proven safe at the dose of 2.4 mg recommended by the FDA and consolidated by several clinical trials conducted in recent years.
References
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism, 19(9), 1242–1251. https://doi.org/10.1111/dom.12932
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2021). Semaglutide for the treatment of obesity. Trends in cardiovascular medicine, S1050-1738(21)00158-4. Advance online publication. https://doi.org/10.1016/j.tcm.2021.12.008
Deng, Y., Park, A., Zhu, L., Xie, W., & Pan, C. Q. (2022). Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Therapeutic Advances in Chronic Disease, 13, 20406223221108064.
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell metabolism, 27(4), 740-756.
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10). https://doi.org/10.1038/S41591-022-02026-4
Hermont, A. P., Zina, L. G., da Silva, K. D., da Silva, J. M., & Martins-Júnior, P. A. (2021). Revisões integrativas em Odontologia: conceitos, planejamento e execução.Arquivos em Odontologia,57, 3-7.
Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
Mendes, K. D. S. et al. (2008). Revisão integrativa: Método de Pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, 17(4), 758-64.
Peters, U.; Dixon, A. E.; & Forno, E. (2018) Obesity and asthma. Journal of Allergy and Clinical immunology, 141(4), 1169-1179, 2018.
Phillips, A., & Clements, J. N. (2022). Clinical review of subcutaneous semaglutide for obesity. Journal of clinical pharmacy and therapeutics, 47(2), 184–193. https://doi.org/10.1111/jcpt.13574
Purdy, J. C., & Shatzel, J. J. (2021). The hematologic consequences of obesity. European Journal of Haematology, 106(3), 306-319.
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/JAMA.2021.23619
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/JAMA.2021.3224
Silva, C. C. et al. (2020). Acesso e utilização de serviços odontológicos por gestantes: revisão integrativa de literatura. Ciência & Saúde Coletiva25,827-835
Simonson, M., Boirie, Y., & Guillet, C. (2020). Protein, amino acids and obesity treatment. Reviews in Endocrine and Metabolic Disorders, 21(3), 341-353.
Sousa, L. M.M., Marques-Vieira, C. M. A., Severino, S. S., & Antunes, A. V. (2017). A metodologia de revisão integrativa da literatura em enfermagem.Rev. Inv. Enferm., 2(21) 17–26. https://repositorio-cientifico.essatla.pt/bitstream/20.500.12253/1311/1/Metodologia%20de%20Revis%c3%a3o%20Integrativa_RIE21_17-26
Souza, M. T. de; Silva, M. D. da; & Carvalho, R. de. (2010) Revisão integrativa: o que é e como fazer. Einstein (São Paulo), 8, 102-106, 2010.
Stadler, J. T., & Marsche, G. (2020). Obesity-related changes in high-density lipoprotein metabolism and function. International Journal of Molecular Sciences, 21(23), 8985.
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., & Garvey, W. T. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/JAMA.2021.1831
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022). Once-Weekly Semaglutide in Adolescents with Obesity. The New England Journal of Medicine, 387(24). https://doi.org/10.1056/NEJMOA2208601
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMOA2032183
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Izadora Pires de Oliveira; Fernando Garcia Lino; Jéssica Laís Rossin Rabano; Juliana Reis Silva; Ligia Zapata de Oliveira; Poliana Pezzotto; Tiago Luis Machado Miranda; Verônica Galvão Brunhara; Éric Àzara de Oliveira; Carollayne Mendonça Rocha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
